

Correction for Chan et al., “A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against Lethal *Streptococcus pneumoniae* Challenge”

Win-Yan Chan,^a Claire Entwisle,^b Giuseppe Ercoli,^a Elise Ramos-Sevillano,^a Ann McIlgorm,^b Paola Cecchini,^b Christopher Bailey,^b Oliver Lam,^c Gail Whiting,^c Nicola Green,^d David Goldblatt,^d Jun X. Wheeler,^c Jeremy S. Brown^a

^aCentre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College Medical School Rayne Institute, London, United Kingdom

^bImmunoBiology Ltd., Babraham, Cambridge, United Kingdom

^cNational Institute for Biological Standards and Control, South Mimms, Potters Bar, Hertfordshire, United Kingdom

^dUCL Great Ormond Street Institute of Child Health, London, United Kingdom

Volume 87, no. 3, e00846-18, 2019, <https://doi.org/10.1128/IAI.00846-18>. Corrections in the Abstract, Materials and Methods, Results, and Discussion were made to the article since an error in labeling one of the batches of the multiple-antigen vaccine (MAV) preparations (specifically, the culture conditions for MAV batch IPS004 [MAV^{IPS004}] and MAV^{IPS005}) caused confusion about interpretation of the results. MAV^{IPS004} and MAV^{IPS005} were cultured at 30°C, with the MAV^{IPS004} also having a short period at 37°C before processing further. Hence, comparison of these products does not properly assess the effects of heat shock on antigenicity. The comparison of these two products remains an important part of the development of the production process for vaccine clinical material, with the comparison of the antigen content between MAV^{IPS004} and MAV^{IPS005} needed to show that reducing the culture temperature to 30°C did not affect the antigenicity of the MAV product. A revised version of the manuscript that corrects these errors is being published simultaneously (<https://doi.org/10.1128/iai.00846-18a>).

Copyright © 2022 American Society for Microbiology. All Rights Reserved.

Published 25 January 2022